Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $248.9 million.

  • Heron Therapeutics' Liabilities and Shareholders Equity rose 12.76% to $248.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $949.9 million, marking a year-over-year increase of 8.03%. This contributed to the annual value of $233.1 million for FY2024, which is 4.78% up from last year.
  • As of Q3 2025, Heron Therapeutics' Liabilities and Shareholders Equity stood at $248.9 million, which was up 7.26% from $232.1 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Liabilities and Shareholders Equity ranged from a high of $404.2 million in Q2 2021 and a low of $201.2 million during Q2 2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $222.5 million (2023), whereas its average is $225.5 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 39.65% in 2022, then increased by 12.76% in 2025.
  • Heron Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $305.7 million in 2021, then declined by 17.91% to $251.0 million in 2022, then declined by 11.33% to $222.5 million in 2023, then grew by 4.78% to $233.1 million in 2024, then rose by 12.76% to $248.9 million in 2025.
  • Its last three reported values are $248.9 million in Q3 2025, $232.1 million for Q2 2025, and $235.8 million during Q1 2025.